With investors focused almost exclusively on earnings and R&D programs today, Merck quietly managed to slip in news of a setback in its quarterly report, noting that the FDA has rejected its marketing application for the fertility treatment corifollitropin alfa.

…read more

Source: Resurgent Merck to accelerate R&D spending in H2, hunt new drug deals


0 No comments